Update on percutaneous intervention for left main coronary artery stenosis
Pil Hyung Lee1, Jung-Min Ahn, Seung-Jung Park
1Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Insights
Drug-eluting stents (DES) offer a viable alternative to coronary artery bypass graft surgery (CABG) for left main coronary artery disease. Updated trial data show comparable outcomes, supporting PCI as a reasonable treatment option.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is an alternative to coronary artery bypass graft surgery (CABG) for left main coronary artery disease (LMACD).
- Landmark trials show comparable 5-year outcomes between CABG and PCI, aligning with current guidelines.
- Previous trials did not include contemporary DES, necessitating further research.
Purpose of the Study:
- To evaluate the role and future recommendations of PCI for LMACD.
- To compare the performance of new-generation DES with CABG.
- To explore integrated approaches for improving PCI outcomes.
Main Methods:
- Analysis of updated results from landmark randomized trials comparing CABG and PCI.
- Ongoing trials evaluating new-generation DES against CABG (e.g., EXCEL trial).
- Review of integrated approaches combining functional decision-making, imaging, and pharmacotherapies.
Main Results:
- Updated trial results demonstrate comparable 5-year outcomes between CABG and PCI for selected LMACD patients.
- Current guidelines support PCI as a reasonable treatment for this subset.
- New-generation DES performance data from ongoing trials are anticipated.
Conclusions:
- PCI with DES is a viable alternative to CABG for selected LMACD patients.
- Ongoing trials with new-generation DES will further refine treatment recommendations.
- An integrated approach, including functional assessment and optimal medical therapy, can enhance PCI outcomes.
Abstract:
Percutaneous coronary intervention (PCI) using drug-eluting stents (DES) is currently considered as a viable alternative to coronary artery bypass graft surgery (CABG) for selected patients with left main coronary artery disease. The updated results of the landmark randomized trials comparing CABG versus PCI demonstrated comparable 5-year outcomes and are in line with the current guidelines that designate PCI as a reasonable treatment in this disease subset. Given that the completed randomized trials did not include contemporary DESs, the upcoming results of the ongoing trials evaluating the performance of new-generation DES compared with CABG (such as the EXCEL trial), may further help to clarify the current role and future recommendations of PCI for left main coronary artery disease. Apart from the recent stent technology, further improvements in outcomes after PCI may be possible when it is used with an integrated approach that combines functional concepts for decision-making, adjunctive imaging support and optimal pharmacotherapies.
Related Concept Videos
Cardiac Catheterization III: Left Heart Catheterization
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Mitral Stenosis III: Medical Management
Acute Coronary Syndrome I: Introduction
Coronary Artery Disease V: Interprofessional Care


